and 50 pM 2-ME) in flat-bottomed microtiter plates in the presence of different concentrations of IL-5 and were incubated for 36 h at 37°C . Cell proliferation was determined by [3H]thymidine uptake (0 .5 uCi/well, sp act 5 mCi/mmol; Radiochemical Centre, Amersham, UK) during the last 12 h of the culture period . 1 U of IL-5 was defined as the amount of IL-5 required for half-maximal proliferation of the B13 cells . IL-5 was also tested for its capacity of promoting maturation of purified small resting C57BL/6 nu/nu splenic B cells to IgM-secreting cells . Small resting splenic B cells were purified by velocity sedimentation as originally described by Miller and Phillips (16) . These cells were then cultured at 5 x 10 5 cells/ml in the presence of different amounts of IL-5 . The number of IgM-secreting cells was determined at day 5 of culture with the use of the protein A plaque assay (17) .
Production of mAbs. Lewis rats were immunized on day 0 with 2 x 10 7 B13 cells emulsified in CFA in the hind foot path . On day 4 and 7 the rats were boosted with 2 x 10 7 B13 Cells in PBS in the same foot path . On day 8 the regional lymph nodes were removed and the cells were fused to the azaguanine-resistant nonsecreting hybridoma cell line SP2/0. 2 x 10 11 fused lymph node cells were plated in 40 microtiter plates in the presence of rat thymocytes (3 x 106 /ml) used as filler cells . Culture wells showing positive growth were tested for the presence of antibodies able to block the IL-5-driven proliferation growth of the B13 cells as follows : B 1 3 cells were cultured in the presence of 5-10 U of murine IL-5 and 10% hybridoma culture supernatant for 36 h . Proliferation of the cells was measured as described above .
For purification of the mAbs, hybridomas R52 .120, R52 .625, and M41 (18) were cultured for 48-72 h in serum-free Iscove's (19) medium containing only transferrin . Antibodies were purified from these supernatants by ion exchange over DEAE-cellulose followed by FPLC on superose-12 (Pharmacia Fine Chemicals, Piscataway, NJ) .
IL-5 Binding Assays . IL-5 was obtained from culture supernatants of X63-Ag-653 myeloma cells transfected with the expression vector BMG neo containing cDNA for mouse IL-5 (15), was purified on an anti-IL-5 column (2) (a gift of Dr. K . Takatsu, Kumamoto University, Kumamoto, Japan), and labeled with 125 1 using the Bolton and Hunter reagent (-4,000 Ci/mmol ; Radiochemical Centre) . IL-5 binding assays were performed as described in detail (10) . In short, B 13 cells were incubated with different amounts 125 1-IL-5 for 45 min at 37°C . A 100-fold excess of unlabeled IL-5 were used to determine nonspecific bindings of 125 1-IL-5 .
Immunofuorescence Staining and Flow Fluorometry. For immunofluorescence studies we routinely used purified mAbs coupled to biotin . Staining of the different cell types was carried out by incubating the cells with 1-5 tLg of biotinylated antibody for 30 min at 4°C . The cells were washed once and resuspended in buffer (PBS plus 5% FCS and 0 .1% NaN3) containing an appropriate dilution of FITC-labeled Streptavidin (Amersham) . Negative controls were cells incubated with FITC-conjugated Streptavidin only. The cells were washed twice in buffer and a third time in buffer containing propidium iodine to exclude dead cells from analysis .
Fluorescence intensity was measured with a FACScan instrument (Becton Dickinson & Co ., Mountain View, CA) . A minimum of 10 4 cells were analyzed per sample . For cell sorting, essentially the same staining protocol was used, with the exception that NaN3 and propidium iodine were omitted . Fluorescence-positive cells were sorted using a FAGS 440 (Becton Dickinson & Co .) equipped with an argon laser tuned to 488 nm, operating at 200 mW power, and the gates set by forward-and side-scatter on the "lymphoid" population of spleen cells .
Immunoprecipitation . B 13 cells were cultured for 6-8 h at a density of 5 x 106 cells/ml in methionine-free RPMI medium (Gibco Laboratories, Grand Island, NY) containing 50 Am 2-ME, antibiotics, 20 U/ml IL-5, 10% dialyzed FCS, and 100 MCi 35 S-methionine/ml (sp act >800 Ci/mmol, Amersham) . Cells were washed three times in PBS and then lysed in a buffer containing 20 mM Tris-HCI, pH 8 .6, 150 mM NaCl, 5 mM MgC12, 5 mM EDTA, 10 mM NaN3, 2% NP-40, and 1 mM PMSF. The cell lysates were processed according to a solid phase immunoprecipitation technique described by Tamura et al . (20) . Immunoprecipitates were analyzed by SDS-PAGE (21) followed by autoradiography using X-ray films (Kodak-X-Omat) .
Results and Discussion
From the fusion of regional lymph node cells of two rats immunized with the IL-5-R+ B13 cell line, 1,750 hybridomas were obtained . Two out of the 1,750 hybridomas, called R52.120 and R52.625, secreted antibodies that consistently and strongly inhibited the proliferation of B13 cells driven by IL-5 . Both R52.120 and R52.625 were cloned and subcloned by limiting dilution and both secrete a rat IgG1/u mAb.
Purified R52 .120 and R52.625 mAbs inhibited the action of IL-5, so that 1 /4g/ml of either antibody suppressed by 60-70% the proliferation of B13 cells promoted by 5 U of IL-5 ( Fig . 1 D) . Neither antibody, even at a concentration as high as 20 hg/ml, had any effect on the proliferation driven by as little as 1 U of IL-2 or IL-4, on their respective target cells (Fig . 1, A and C) . Similarly, the mAbs did not inhibit the IL-3-induced proliferation of three IL-3-reactive cell lines (illustrated with one example in Fig. 1 C) . A special case is the B13 cell line, used to produce the IL-5-Rspecific mAbs R52.120 and R52 .625, which respond to both IL-3 and IL-5 . High concentrations (20 ug/ml) of both mAbs inhibited by 50% the proliferative response to IL-3 . The inhibitory effect of the antibodies on the IL-3-driven response of B13 cells but not of the other IL-3-sensitive cell lines might indicate an interesting connection of the IL-3 and IL-5 responsiveness and, therefore, of the corresponding receptors on B13 cells.
Next we tested R52.120 and R52.625 mAbs for their capacity of inhibiting binding of radiolabeled IL-5 to B13 cells. The target cells incubated with [ 125 ]IL-5 and a 100-fold excess of unlabeled IL-5 was used to determine nonspecific binding of [125I]IL-5; the isotype-matched rat anti-mouse IgM mAb M41 (16) was used as negative control antibody in these experiments. The results (Fig . 2) show that both R52.120 and R52 .625 mAbs blocked the specific binding of radiolabeled IL-5 to B13 cells. 1 jug/ml of either antibody inhibited by >40% the binding of IL-5 to B13 cells. No inhibition of the IL-5 binding to these cells was observed with the irrelevant isotypematched control antibody (Fig . 2) . Moreover, neither R52.120 nor R52.625 mAbs blocked the binding of [ 125 1]transferrin to the same B13 Cells. We conclude that the mAbs R52 .120 and R52 .625 react against the IL-5-R and that the epitopes recognized by them in the receptors must be very close or identical to the IL-5 binding sites.
The next set of experiments was performed to study by immunofluorescence staining and side-scatter) had 10-15 17o positive cells for both R52.120 and R52 .625 mAbs (Fig .  3 E) . Peritoneal cells were also found to contain N10-14% cells that bind both antibodies . Previous studies have shown that IL-5 promotes maturation of B lymphocytes into antibody-secreting cells (PFC) (7) . In light of the finding that both R52.120 and R52.625 mAbs consistently bound to 2-4% lymphoid splenocytes, we wished to know whether among these cells would be B cells responsive to IL-5 . Thus, R52.120 + lymphoid splenocytes were isolated by cell sorter and tested for their capacity to mature into antibody-secreting cells (PFC) in the presence of IL-5 . Table  I summarizes the results of four experiments. It shows that the frequency of IL-5-inducible PFC increased by a factor of 15-20 in the R52.120' cell sorter-purified population as compared with that observed in the unsorted population (Table I) . In fact, the frequency of PFC in purified R52.120 + spleen cells stimulated by IL-5 was similar to that obtained with these cells in the cultures stimulated by LPS (Table  I) . We conclude that among the R52.120' spleen cells, there are B lymphocytes able to mature into antibody-producing cells upon exposure to IL-5 .
Yet another piece of experimental evidence for the existence of IL-5-reactive B lymphocytes in mouse spleen is the experiment in which both R52.120 and R52 .625 mAbs inhibited the IL-5-induced maturation of spleen cells to IgM-secreting cells (Table II) . These types of experiments were performed with small, resting spleen cells purified by velocity sedimentation (16) . However, since the population of IL-5-reactive B cells is small, we cannot completely exclude that some of the B cells that respond to IL-5 in this system have been preactivated in vivo. In the same experiment these mAbs did not inhibit the IL-2-induced maturation of the spleen B cells, while anti-IL-2-R mAbs did (Table II) .
We have begun the biochemical characterization of the antigens recognized by the R52 .120 and R52 .625 mAb. These antibodies are likely to interact with the same or with sterically close epitopes on the IL-5-R as they block each other's binding to B13 cells. We found that both antibodies specifically precipitate from cell lysates of "S-methionine-labeled B13 cells three proteins with apparent Mr of 46,000, 130,000, and 140,000 under reducing (Fig. 4) Small resting B cells (at a concentration of 5 x 105 cells/ml) were stimulated with 100 U/ml IL-2 or 5 U/ml IL-5 . IgM-secreting cells were determined at day 5 of culture as described (7) . * The mAbs R52 .120 and R52 .625 (10,ug/ml) and the anti-IL-2-R antibodies (23, 24) (final concentration 10% hybridoma culture supernatant) were added at the beginning of the cultures . The binding of radiolabeled IL-5 to its receptor followed by crosslinking of this complex have so far revealed only a single IL-5 binding protein ofMr 45,000-50,000 (2, 10) . On the basis of these molecular weight analyses, it is tempting to speculate that the IL-5 binding protein corresponds to the Mr 46,000 molecule recognized by mAbs R52.120 and R52 .625.
Our knowledge of the binding of IL-5 and the nature of the receptor identified by either IL-5 binding or mAb binding leaves us with at least two possible models for the IL-5-R . In the first model the IL-5-R is a complex of three proteins with Mr 45,000-50,000, 130,000, and 140,000, in which Mr 45,000-50,000 is the only IL-5 binding protein and Mr 130,000 and 140,000 are possibly involved in signal transduction . Since IL-5 is biologically active only in its dimeric form (2, 10) , low affinity binding would be the binding of IL-5 to one of these protein complexes, whereas high affinity IL-5 binding would represent the crosslinking of two of these complexes . The finding that the monomeric biologically inactive form of IL-5 binds to the IL-5-R complex with low affinity and can block the high affinity binding ofthe dimeric form of IL-5 (unpublished results) supports this M, 45,000-50,000 homodimer binding model.
The second model would be that the IL-5-R is a "hetero"protein complex in which M, 45,000-50,000 is the IL-5 binding protein giving rise to only low affinity binding. For high affinity binding the IL-5 should have to interact with a second protein, maybe with M, 130,000 and/or 140,000 . This second model would be comparable with the model for the IL-2-R . In the case of the IL-2-R, it is known that the presence ofboth p70 and p55 are necessary for binding of IL-2 with high affinity; p55 alone binds IL-2 with low affinity, while p70 alone binds it with intermediate affinity (22) . Thus far, a second IL-5 protein has not yet been identified, and in particular, IL-5 binding to the M, 130,000 or 140,000 proteins has not yet been observed.
Ultimate proof for the nature of the IL-5-R will have to come from cloning of the genes encoding this receptor and subsequent functional tests by transfection experiments . The availability of monoclonal anti-IL-5-R antibodies and cell lines expressing high levels of IL-5-R with capacity ofunlimited growth should now greatly facilitate this cloning as well as the study ofthe mechanism of action and the biological relevance of IL-5.
Summary
The rat mAbs R52 .120 and R52 .625 inhibit the action of IL-5 on both IL-5-sensitive cell lines and freshly isolated splenic B lymphocytes . Neither antibody inhibits the proliferative cell responses promoted by IL-2, IL-3, or IL-4. Purified R52.120+ lymphoid spleen cells contain 15-20-fold higher numbers of B lymphocytes responding to IL-5 in the form ofmaturation into antibody-producing cells. By immunofluorescence staining and flow fluorocytometry, the R52 .120 and R52.625 antibodies bound to all 12 IL-5-sensitive cell lines tested. Both antibodies react with 2-4% cells in the spleen, 517o lymphoid cells, and 10-1517o myeloid cells in the bone marrow, and 10-14% in the peritoneum of C57BL/6, DBA/2, and BALB/c adult mice. No positive cells for either antibody were detected in the thymus and lymph nodes of these mice. Both R52.120 and R52 .625 antibodies specifically inhibit the binding of radiolabeled IL-5 to its receptor. Finally, R52 .120 and R52 .625 antibodies precipitate from 15 S-methionine-labeled IL-5-R`cell lysates three proteins with M, 46,000, 130,000, and 140,000 . Taken together from these results, we conclude that the R52 .120 and R52 .625 mAbs recognize epitopes on the IL-5-R complex very close or identical to the IL-5 binding sites.
